

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Dhanoa et al.  
SERIAL NUMBER: 10/815,417 EXAMINER : Not Yet Assigned  
FILING DATE: March 31, 2004 ART UNIT : 1614  
FOR: NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE  
COMPOUNDS

**Mail Stop Amendment**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required. By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A5 are not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Dhanoa et al.  
U.S.S.N.: 10/815,417

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24591-510.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

Nicholas P. Triano, III, Reg. 36,397

Attorney(s) for Applicants

c/o MINTZ, LEVIN

Address all written correspondence to


**Customer no.: 30623**

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: May 4, 2005

TRA 2032061v1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Dhanoa et al.  
SERIAL NUMBER: 10/815,417 EXAMINER : Not Yet Assigned  
FILING DATE: March 31, 2004 ART UNIT : 1614  
FOR: NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE  
COMPOUNDS

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of Cited References: B1-7; C1-4; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24591-510. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Nicholas P. Triano, III, Reg. 36,397

Attorney(s) for Applicants

c/o MINTZ, LEVIN

Address all written correspondence to

**Customer no.: 30623**

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: May 4, 2005



Please type a plus sign (+) in this box

PTO/SB (12-97)  
Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	10/815,417
	<b>Filing Date</b>	March 31, 2004
	<b>First Named Inventor</b>	Dhanoa
	<b>Group Art Unit</b>	1614
	<b>Examiner Name</b>	Not Yet Assigned
	<b>Attorney Docket Number</b>	24591-510

**U.S. PATENT DOCUMENTS**

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	3,658,807	04/25/72	Schmidt et al.	260	247.1	
	*A2	5,227,387	07/13/93	Dreikorn et al.	514	312	
	*A3	5,571,815	11/05/96	Schaper et al.	514	269	
	*A4	6,300,333 B1	10/09/01	Schaper et al.	514	256	
	*A5	6,596,727 B1	07/22/03	Schaper et al.	514	269	

**U.S. PUBLISHED APPLICATION DOCUMENTS**

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 94/22871	SMITHKLINE BEECHAM PLC	10/13/94	
	B2	WO 01/14333 A1	ASTRAZENECA UK LIMITED	03/01/01	
	B3	WO 01/25218 A1	ENERGY CORPORATION	04/12/01	Abstract Only
	B4	WO 02/102797 A1	BIOFRONTERA AG	12/27/02	
	B5	WO 2004/017950 A2	PIRAMED LIMITED	03/04/04	
	B6	EP 1 229 025 A1	JAPAN ENERGY CORPORATION	08/07/02	
	B7	GB 2 295 387 A	GLAXO INC.	05/29/96	

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Brea et al. <i>J. Med. Chem.</i> , 45:54-71 (2002)
	C2	Launay et al. <i>Nat. Med.</i> , 8(10):1129-1135 (2002)
	C3	Manivet et al. <i>J. Biol. Chem.</i> , 277(19):17170-17178 (2002)
	C4	International Search Report for PCTY/US04/09944, mailed March 1, 2005.

\* By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A5 are not submitted.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.